Vitamin D and interferon-γ co-operate to increase the ACE-2 receptor expression in primary cultures of human thyroid cellsArticle Published on 2022-11-012022-11-15 Journal: Journal of Endocrinological Investigation [Category] COVID19(2023년), SARS, 진단, [키워드] ACE-2 ACE-2 receptor angiotensin Cell Cell culture cell membrane cells chain Combination combination treatment Course COVID-19 defend demonstrated experiment expressed expression Host IFN-γ immune defense immunocytochemistry in vitro data interferon-γ material membrane mRNA mRNA level observation primary culture Protein protein level reaction receptor RT-PCR SARS-CoV-2 shown supported Therapeutic benefit Thyrocytes Thyroid tissue treated Treatment up-regulate up-regulated up-regulating Vitamin D were measured would increase [DOI] 10.1007/s40618-022-01857-9 PMC 바로가기
ColdZyme® protects airway epithelia from infection with BA.4/5Article Published on 2022-10-312022-11-16 Journal: Respiratory Research [Category] COVID19(2023년), SARS, 변종, [키워드] Activation administration airway airway epithelia applied BA.4 BA.5 block blocked complement contagious Critical Culture epithelial in vitro data Infection Inflammation inflammatory reaction Intervention intrinsic omicron Pathogenesis prevented Prophylaxis PROTECT respiratory tissue SARS-CoV-2 SARS-CoV-2 transmission significantly subsequent Transmission variants variants of concern Viral transmission virus infection VoC VOCs while [DOI] 10.1186/s12931-022-02223-2 PMC 바로가기
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants중증급성호흡기증후군 코로나바이러스 2 델타 및 오미크론 변이체에 대한 단일클론항체의 임상적 효능 및 시험관내 중화능Article Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Casirivimab casirivimab/imdevimab clinical Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient decrease delta variant dosage Efficacy except for exhibit Hospital stay Imdevimab in vitro in vitro data in vivo Infection mAb mAbs monoclonal monoclonal antibodies monoclonal antibody neutralization Neutralization assay neutralization capacity neutralizing capacity neutralizing effect Omicron variant Patient patients treated performed provided receiving respiratory respiratory tract respiratory viral RNA SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 RNA severe acute respiratory syndrome Coronavirus sotromivab Sotrovimab the SARS-CoV-2 therapeutic therapy treated variant Viral Virus neutralization virus neutralization assay virus neutralization assays [DOI] 10.1002/jmv.27916 PMC 바로가기 [Article Type] Article
Current status of antihistamine drugs repurposing for infectious diseasesReview article Published on 2022-09-012022-10-05 Journal: Medicine in Drug Discovery [Category] 신약개발, [키워드] active against Anti-infective Antihistamines applicability article Blood brain barrier Candida carried Chemical library clinical trial clinical trials cross current determine dose drug Ebola virus Efficacy English eventual need FIVE Google Scholar Government groups growth Health hepatitis C IC50 identify in vitro activity in vitro data in vivo Infectious disease information inhibited intrinsically lack Leishmania objective off-label Pathogens pharmacological Plasmodium repurposing Research Result rodents Side effects Staphylococcus aureus Staphylococcus epidermidis Support suppressed Trial Trypanosoma virus [DOI] 10.1016/j.medidd.2022.100140 [Article Type] Review article
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2뉴클레오사이드/뉴클레오타이드 유사체 테노포비르와 엠트리시타빈은 SARS-CoV-2에 대해 비활성입니다Article Published on 2022-06-302022-09-11 Journal: Molecules [Category] COVID19(2023년), SARS, 치료제, [키워드] accelerated active site acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antiviral activity antiviral agent Antiviral agents Antiviral effect approaches approved approved drug biochemical causative pathogen caution Cell clinicians and researcher Concentration coronavirus COVID-19 COVID-19 pandemic demonstrated Efficiency emtricitabine epithelial FTC HIV-1 HIV-1 NRTI human lung in vitro data inactive indicate inhibitor lack metabolite NHBE NTP nucleoside polymerase Prevent RdRP RdRp active site required reverse transcriptase RNA polymerase SARS-CoV-2 SARS-CoV-2 RNA severe acute respiratory syndrome Coronavirus TAF TDF tenofovir Tenofovir alafenamide the SARS-CoV-2 transcriptase treat unlikely [DOI] 10.3390/molecules27134212 PMC 바로가기 [Article Type] Article
Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variantsSARS-CoV-2 변이체에 대한 니르마트렐비르의 시험관내 효능에 대한 구조적 기초Article Published on 2022-06-012022-09-11 Journal: The Journal of Biological Chemistry [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] Alpha B.1.1.529 B.1.1.7 B.1.351 Beta biochemical catalytic activity catalytically cells comparable COVID-19 pandemic crystal structure Delta Efficacy enzymatic assay enzyme evaluated Frequency Gamma in vitro in vitro data inhibitor Ki Lambda M pro M(pro) maintain molecular basis mutant Mutation Nirmatrelvir observation omicron Omicron variant P.1 Paxlovid PF-07321332 plasma concentration plasma concentrations potency prevalent protease Protease inhibitor provided public health threat required Ritonavir SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Tablet tablets the SARS-CoV-2 variant variants variants of concern variants of interest variants of SARS-CoV-2 VoC VOCs VOIs Washington wildtype [DOI] 10.1016/j.jbc.2022.101972 PMC 바로가기 [Article Type] Article
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvirSARS-CoV-2 변이체의 주요 프로테아제 돌연변이체는 여전히 니르마트렐비르에 감수성입니다Article Published on 2022-04-152022-09-11 Journal: Bioorganic & medicinal chemistry letters [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] anticipated antiviral agent Antiviral agents B.1.1.529 B.1.351 Beta catalytically competent Coronaviral COVID-19 COVID-19 pandemic drug target Effectiveness Efficacy expressed in vitro data inhibitor inhibitors Lambda M pro main protease Missense mutation Multiple multiple mutations mutant Mutation Nirmatrelvir not compromised omicron P.2 PF-07321332 prevalent protease public health threat SARS-CoV-2 SARS-CoV-2 lineage SARS-CoV-2 variant Specific Spike protein susceptible the spike protein Vaccines variant variants variants of SARS-CoV-2 wildtype [DOI] 10.1016/j.bmcl.2022.128629 PMC 바로가기 [Article Type] Article
Repurposing drugs for treatment of SARS-CoV-2 infection: computational design insights into mechanisms of actionSARS-COV-2 감염의 치료를위한 약물 용도 : 작용 메커니즘에 대한 전산 설계 통찰력Article Published on 2022-02-012022-08-31 Journal: Journal of biomolecular structure & dynamics [Category] COVID19(2023년), MERS, SARS, 신약개발, 치료법, 치료제, [키워드] accelerate binding site Broad Institute caused ChEMBL Compound Computational drug Coronavirus infection COVID-19 COVID-19 pandemic database deaths determine develop drug Drug development Drug repurposing feature Features health emergency help human population identify in vitro in vitro data in vivo inhibit inhibitors inhibitors of SARS-CoV-2 Interaction life Ligand mechanism molecules negatively affected non-structural proteins Novel coronavirus Novel coronavirus infection nucleocapsid nucleocapsid protein pharmacophore predicted progressed Protein Protein binding Protein target protein targets repurposing Research SARS-CoV-2 SARS-CoV-2 genome screened the SARS-CoV-2 genome therapeutic intervention therapeutic interventions Treatment Viral Viral protein Viral proteins Virtual screening virus Visualisation was used [DOI] 10.1080/07391102.2020.1825232 PMC 바로가기 [Article Type] Article
An in silico analysis identifies drugs potentially modulating the cytokine storm triggered by SARS-CoV-2 infection실리코 분석은 SARS-CoV-2 감염에 의해 유발된 사이토카인 폭풍을 잠재적으로 조절하는 약물을 식별합니다Article Published on 2022-01-312022-09-10 Journal: Scientific Reports [Category] 신약개발, 유전자 메커니즘, 치료제, [키워드] “cytokine storm” addition Analysis anti-inflammatory properties anti-inflammatory property approach BALF Bronchoalveolar lavage fluid cause causes Computational biology and bioinformatics connectivity COVID-19 COVID-19 mortality COVID-19 pandemic COVID-19 patient Cytokines Data mining dataset drug Effect expected female hormone glucocorticoid Glucocorticoids Health help human cell lines identify immune response immune responses in silico analysis in vitro data Inflammatory Map MEK inhibitor modulating molecules Mortality negative regulation pathology pathway Pathways PKC predicted reveal SARS-CoV-2 SARS-COV-2 infection small molecule Small molecules supported the cytokine storm these compounds Transcription Transcriptome transcriptomic data Treatment triggered [DOI] 10.1038/s41598-022-05597-x PMC 바로가기 [Article Type] Article
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster modelArticle Published on 2022-01-012022-10-04 Journal: Antiviral Research [Category] SARS, 신약개발, [키워드] airway airway epithelia antiviral drug antiviral molecule antivirals Azithromycin cell lines Clinical course clinical trial concentrations coronavirus COVID-19 COVID-19 pandemic doses drug effective Ex vivo Human Human airway epithelium Hydroxychloroquine identify in vitro in vitro data in vivo inhibitory inhibitory activity lung lung tissue no significant effect quantification SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 replication shown Support Syrian hamster. tested the disease Treatment use of hydroxychloroquine viral replication weakness [DOI] 10.1016/j.antiviral.2021.105212 PMC 바로가기 [Article Type] Article